Navigation Links
Pharmacyclics to Announce Third Quarter Fiscal 2011 Results and Host a Conference Call on May 4, 2011
Date:4/29/2011

SUNNYVALE, Calif., April 29, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC), a clinical stage biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer and immune mediated diseases, today announced that senior management will host a conference call and live audio webcast on Wednesday, May 4th, at 4:30 pm ET to discuss the company's third quarter fiscal 2011 financial and operational results. Conference Call and Webcast Details:Date: Wednesday, May 4, 2011Time: 4:30 pm ETListen via Internet: http://ir.pharmacyclics.com/events.cfm Toll-free: +1-877-407-8133International: +1-201-689-8040The webcast replay will be available for 30 days on the Investor Relations section of the company's Web site at www.pharmacyclics.com.

About PharmacyclicsPharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has four product candidates in clinical development and several preclinical molecules in lead optimization. We are committed to high standards of ethics, scientific rigor, and operational efficiency as we move each of these programs to viable commercialization.

The Company is h
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)...  TNI BioTech, Inc. (OTCQB: TNIB) ("TNIB" or ... development, marketing and distribution of opioid-related immunotherapies, announced ... with the Securities and Exchange Commission in connection ... be held on Thursday, September 4, 2014, at ... for determining those shareholders eligible to receive notice ...
(Date:7/28/2014)... , July 28, 2014 Concord Medical Services ... CCM ), a leading specialty hospital management solution ... and diagnostic imaging centers in China ... Board of Directors declared a special cash dividend of ... Share ("ADS")) on the Company,s outstanding ordinary shares. The ...
(Date:7/28/2014)... 2014 OmPrompt gab ... £ investiert hat, um die weltweite Nachfrage ... und Logistikbranche zu erfüllen. Albion wird Teil ... http://photos.prnewswire.com/prnh/20140728/697982 ) In ... beschleunigtes Wachstum mit Investitionen in seine Plattform, ...
Breaking Medicine Technology:TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 3Concord Medical Declares Special Dividend 2OmPrompt erhält Finanzierung für Marktexpansion von Kundenautomatisierungsmanagement 2
(Date:7/28/2014)... (PRWEB) July 28, 2014 With California ... it is welcome news that a fire blanket ... current protection is under development by SunSeeker Enterprises, Inc. ... to protect spacecraft from the extreme heat of re-entry ... both firefighters and homes. , “Our firefighters routinely lay ...
(Date:7/28/2014)... bumping" transmits significantly fewer bacteria than either handshaking ... of hand-to-hand contact between patients and clinicians, according ... of the American Journal of Infection Control ... Professionals in Infection Control and Epidemiology (APIC). , ... Environmental, and Rural Sciences at Aberystwyth University in ...
(Date:7/28/2014)... North America Carotenoids & Antioxidants Market report defines and segments ... and forecast of revenue. This market is estimated to grow ... 2018, at a CAGR of 7.1% from 2013 to 2018. ... & Antioxidants Market report to get an idea of the ... segmentation in the market, and is supported by various tables ...
(Date:7/28/2014)... the July, 2014, issue of the Journal ... Medicine researchers, sheds new light on the risks ... in the treatment of localized, early-stage esophageal cancer. ... while more invasive, provided significantly better outcomes with ... than endoscopic resection, which had a 76 percent ...
(Date:7/28/2014)... New York (PRWEB) July 28, 2014 ... edition of “Organic Living” on March 12th, a campaign ... an organic lifestyle. In partnership with industry leader ... over 100 Certified Organic teas, the campaign provides readers ... recent years that continues to propel the industry forward ...
Breaking Medicine News(10 mins):Health News:Revolutionary Fire Blanket Offers Over 200 Percent More Fire Protection to Firefighters and Homes 2Health News:Fist-bumping beats germ-spreading handshake, study reports 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Study helps compare risks of treatments for early esophageal cancer 2Health News:Study helps compare risks of treatments for early esophageal cancer 3Health News:Mediaplanet's "Organic Living" Campaign Raises Awareness About What Nature Invented, With the Help of Partner TEALUX 2
... -- A Wayne State University study published in the January ... that two influential early studies of cellphone use and crash ... cellphones while driving. In this new study, Richard Young, ... Psychiatry and Behavioral Neurosciences in the School of Medicine, examined ...
... HealthDay Reporter , WEDNESDAY, Dec. 14 (HealthDay News) ... may one day also prove useful in combating serious cases ... Journal of Infectious Diseases finds that patients hospitalized with ... a statin, compared with their peers who weren,t taking one ...
... Institute for Operations Research and the Management Sciences (INFORMS) ... Society Frank P. Ramsey Medal to Dr. Don N. ... market leading provider of web-based financial analytics and performance ... health systems to enhance their financial planning, budgeting, and ...
... by some as being a potent stimulant, but the debate ... of expert opinions capture the scope of this ongoing debate ... Caffeine Research , a quarterly peer-reviewed journal from Mary Ann ... www.liebertpub.com/jcr . Led by Journal of Caffeine Research ...
... Lyon has developed an animal model carrying a mutation of the ... can no longer induce the death of the cancer cells. This ... treatment that aims to reactivate the dying of cancer cells. ... in the 11th December 2011 issue of the journal Nature ...
... face a steep learning curve to get used to new ... before new total knee replacement procedures are as safe and ... operations using a new device in a hospital are 48 ... undergoing an operation to fit a prosthesis previously used in ...
Cached Medicine News:Health News:Wayne State study shows early research on cellphone conversations likely overestimated crash risk 2Health News:Could Statins Help Those Hospitalized With Flu? 2Health News:INFORMS presents Ramsey Medal to health care financial analytics executive Don Kleinmuntz 2Health News:A gene that protects against colorectal cancers 2Health News:Patients at risk of knee joint complications when new technology is used 2
The S8 Escape is the economy model of ResMeds S8 series. The S8 Escape is ideal for patients who want the convenience and portability of the S8 models but do not require the added comfort features of...
... REMstar Plus with C-Flex combines ... and the comfort of C-Flex.With ... REMstar Plus with C-Flex offers ... deliver sleep therapy by taking ...
... a display, ramp capabilities and ... has features that make set-up ... meter records the number of ... four hours - giving you ...
REMstar Pro with C-Flex is a combination of the advances from our other products. The difference is the C-Flex waveform which offers a more comfortable way to deliver sleep therapy by taking the work...
Medicine Products: